# Shikonin Evidence by Cancer Type This section groups the shikonin evidence into cancer-specific pages. That matters because shikonin is not equally relevant in every tumour type. Its strongest mechanisms depend on context. PKM2 dependence, estrogen signalling, EMT biology, and resistance patterns differ between cancers. ### Available pages * [**Breast Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/breast-cancer.md) — strongest current case, with ER-pathway disruption, PKM2 relevance, necroptosis, and tamoxifen synergy * [**Bladder Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/bladder-cancer.md) — most complete resistance-reversal story, centred on PKM2 and cisplatin resistance * [**Oesophageal Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/oesophageal-cancer.md) — one of the better-supported non-breast settings, with PKM2 and STAT3-linked glycolysis suppression plus in vivo data * [**Ovarian Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/ovarian-cancer.md) — microenvironment-focused evidence, especially exosome and macrophage biology * [**Cervical Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/cervical-cancer.md) — early but specific work on EMT suppression and PI3K/AKT/mTOR-related signalling * [**Lung Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/lung-cancer.md) — PI3K/AKT/mTOR relevance and derivative-based gefitinib sensitisation findings * [**Thyroid Cancer**](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/thyroid-cancer.md) — emerging ferroptosis signal in anaplastic thyroid cancer If a cancer type is not listed here yet, it can be added later as the literature grows. ### Why the structure matters A finding in one cancer type does not automatically transfer to another. ERα degradation matters far more in luminal breast cancer than in bladder cancer. Ferroptosis may matter in anaplastic thyroid cancer without being central elsewhere. That is why shikonin needs a cancer-by-cancer structure rather than one merged summary. ### Human evidence outside oncology Shikonin has more human-level evidence outside oncology than inside it. That still does not make the evidence strong. Most human-relevant data involve whole-herb formulas, topical preparations, ex vivo human cells, or alkannin rather than isolated shikonin.
See the full non-oncology human-evidence breakdown #### Psoriasis — strongest human signal This is the clearest clinical area. A 2022 systematic review and meta-analysis pooled 11 clinical trials with 1,024 participants using Chinese herbal formulas containing *Lithospermum erythrorhizon* as the primary herb. PSASI scores improved significantly. The limit is decisive. These were multi-herb formulas, not isolated shikonin. [Systematic review and meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC9128614/) #### Wound healing — older clinical signal An older clinical trial in 72 patients with varicose leg ulcers used topical alkannin esters. Healing results were favourable. This was alkannin, not shikonin, and it was topical only. Human skin-cell work also supports a wound-healing mechanism, with increased keratinocyte and dermal-fibroblast proliferation without excess collagen production. [Wound-healing review and clinical context](https://pmc.ncbi.nlm.nih.gov/articles/PMC4717985/) #### COPD — ex vivo human immune-cell evidence A 2020 study collected PBMCs from 10 patients with COPD and treated them ex vivo with shikonin. At non-cytotoxic concentrations, shikonin reduced LPS-induced TNF-α production and NF-κB activation. That confirms activity in human immune cells. It does not show treatment benefit in patients. [Ex vivo COPD PBMC study](https://pmc.ncbi.nlm.nih.gov/articles/PMC7480124/) #### Atopic dermatitis — small oral trial A randomised placebo-controlled trial enrolled 28 participants with atopic dermatitis and used oral gromwell extract for 10 weeks. Overall SCORAD improvement was not statistically significant. This was whole-herb extract, not standardised isolated shikonin. [Atopic dermatitis trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC4904053/) #### Hypertrophic scarring — human tissue-derived fibroblast work Shikonin reduced collagen overproduction and increased apoptosis in hypertrophic scar-derived human fibroblasts. This is more translatable than standard immortalised cell-line work. It is still in vitro. [Human fibroblast study](https://www.sciencedirect.com/science/article/abs/pii/S0009279715000034) #### Anti-HIV — in vitro human-cell evidence Shikonin inhibits HIV-1 reverse transcriptase and has shown strong inhibition of viral invasion in vitro at non-cytotoxic concentrations. There is no clinical HIV evidence. [Review including anti-HIV data](https://pmc.ncbi.nlm.nih.gov/articles/PMC10745356/) #### Immune diseases more broadly — still preclinical Multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, asthma, and type 1 diabetes remain preclinical topics. The recurring mechanisms are NF-κB suppression, NLRP3 modulation, and macrophage polarisation. No clinical trials with isolated shikonin were reported. [Immune-disease review](https://pubmed.ncbi.nlm.nih.gov/37454591/) #### What this means for oncology The main takeaway is mechanistic, not clinical. Human psoriasis data and ex vivo COPD data support that shikonin-related anti-inflammatory effects are not just theoretical. NF-κB and TNF-α suppression appear to operate in human-relevant systems. That strengthens the broader biology. It does not close the oncology gap. There are still no human cancer trials, and no established systemic dose for cancer use.
### Key references Ahmad F et al. (2024). Shikonin in breast cancer treatment: comprehensive review. *Journal of Pharmacy and Pharmacology.*\ Frontiers in Pharmacology (2025). Shikonin in female reproductive cancers.\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.